Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties
Broker upgrades boost URBN, INGN and SWX, with earnings growth and strong Zacks Ranks signaling potential upside despite market volatility.
What Makes Inogen (INGN) a New Buy Stock
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)
Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.
A Volatile Share Price Masks Some Of The Progress At Inogen
Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.
